Planview Scores Highest for Single Lean/Kanban Team and SAFe Use Cases in 2020 Gartner® Critical Capabilities for Enterprise Agile Planning Tools
Planview® today announced it has ranked highest for both the Single Lean/Kanban Team and Scaled Agile Framework® (SAFe) Use Cases in the Gartner “Critical Capabilities for Enterprise Agile Planning Tools*” report. The research assessed 16 enterprise Agile planning tool offerings across six use cases. In addition to receiving the highest score in the Single Lean/Kanban Team and SAFe Use Cases, Planview received the second highest scores in the Distributed Agile and the Project and Program Portfolio Use Cases.
“The key to success in any Agile transformation is leveraging solutions that empower your teams at every stage of the journey,” said Patrick Tickle, Planview Chief Product Officer. “We’re pleased to be recognized by Gartner for the Single Lean/Kanban Team and SAFe Use Cases. We believe these two methods are at the core of today’s transformations – scaling with SAFe and the accelerating use of Kanban to support continuous delivery and business agility.”
In today’s fast-paced, highly disruptive markets, teams must leverage a variety of work methodologies and processes to get work done, such as Lean, Agile, Scrum, Kanban, Scrumban, and traditional project delivery. Planview’s full spectrum of Portfolio and Work Management solutions help enterprises transform strategy to delivery. In particular, Planview’s approach to Enterprise Kanban ensures organizations, from the Agile teams to the business, can continue to deliver value quickly and effectively, without giving up visibility and management to broader strategic outcomes.
Planview was also recently recognized as a Leader in the 2020 Gartner Magic Quadrant for Enterprise Agile Planning Tools **, which positioned the company as highest on the ability to execute axis. The 2020 Gartner Critical Capabilities for Enterprise Agile Planning Tools research complements the companion 2020 Gartner Magic Quadrant for Enterprise Agile Planning Tools, and looks at product capabilities and how those capabilities can be applied to use cases.
To learn more about the Planview Lean and Agile Delivery Solution visit: planview.com/lean-agile-delivery.
Additional Resources:
- Blog: Lean into the Changing World of Work
- Guide: The Ultimate Lean and Agile Software Solution Buyer’s Guide
- Whitepaper: 7 Benefits of Scaling Agile
- 3 Minute Pathfinder: Lean-Agile Pathfinder
- Follow the Planview Blog
- Connect with Planview on Twitter, Facebook and LinkedIn
*Gartner, Critical Capabilities for Enterprise Agile Planning Tools by Mike West, Keith Mann, Bill Blosen, Akis Sklavounakis, Deacon D.K Wan, April 29, 2020
**Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Keith Mann, Mike West, Bill Blosen, Akis Sklavounakis, Deacon D.K Wan, April 21, 2020
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit https://www.planview.com/.
Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005447/en/
Contact information
Leslie Marcotte
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom